CN101988060A - Marker for detecting colon and rectum cancer as well as detection method, kit and biological chip thereof - Google Patents
Marker for detecting colon and rectum cancer as well as detection method, kit and biological chip thereof Download PDFInfo
- Publication number
- CN101988060A CN101988060A CN2010102384489A CN201010238448A CN101988060A CN 101988060 A CN101988060 A CN 101988060A CN 2010102384489 A CN2010102384489 A CN 2010102384489A CN 201010238448 A CN201010238448 A CN 201010238448A CN 101988060 A CN101988060 A CN 101988060A
- Authority
- CN
- China
- Prior art keywords
- mir
- seq
- mirna
- colorectal cancer
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to a marker for detecting colon and rectum cancer by utilizing 86 specific ribonucleic acids stably existing in the serum/plasma of a human body, as well as a method, a relevant kit and a biological chip for detecting the marker. The method can be used in the aspects of diagnosing and differentially diagnosing the colon and rectum cancer and predicting the generation and the recurrence of the complications of diseases, evaluating the curative effect, screening the active ingredients in drugs, evaluating the drug effect and the like, and has the advantages of wide detection pedigree, high sensitivity and low detection cost, material is convenient for obtainment, samples are easy to store and the like. The method can be widely used for generally surveying the colon and rectum cancer and relevant work and improving low specificity and low sensitivity which are brought by the individual difference difficultly and are difficult to overcome by the single marker, thereby obviously enhancing the clinical detection rate of the colon and rectum cancer and becoming an effective means for early diagnosing the colon and rectum cancer.
Description
Technical field
The invention belongs to biological technical field, relate to separation, the qualitative and quantitative analysis of miRNA molecule in the human serum, also relate to the various clinical indication of colorectal cancer simultaneously.Specifically, the present invention is a kind of method that detects miRNA in colorectal cancer patients serum/blood plasma, variation by miRNA in colorectal cancer patients serum/blood plasma, in the in-vitro diagnosis colorectal cancer, judge the colorectal cancer pathogenic process, the generation of prediction colorectal cancer complication and the probability of colorectal cancer recurrence and the prognosis of colorectal cancer, and analyze drug effect and curative effect.
Background technology
Colorectal cancer is a common malignant neoplasm in digestive tract, and incidence is only second to cancer of the stomach and esophagus cancer.In China's common cancer death, colorectal cancer patients accounts for the 5th the male sex, and the women accounts for the 6th.Recent two decades comes the sickness rate of colorectal cancer increasing gradually, simultaneously, and its age of onset trend aging.At western developed country, colorectal cancer is the second malignant neoplasm that is only second to lung cancer.The sickness rate of country variant differs 60 times.Predilection site is rectum and rectum and sigmoid colon intersection, accounts for 60%.Morbidity is many at 60～70 years old, and the right side of fifty is less than 20%.
The diagnosis of colorectal cancer is mainly according to digital rectal examination, rectoscope or sigmoidoscopy and barium enema, fibercolonscopy result.The colorectal cancer early symptom is not true to type, even asymptomatic, and by mistaken diagnosis, misdiagnosis rate is up to 30% through regular meeting.Therefore, seek colorectal cancer marker and it is accurately detected the extremely urgent and important precondition of the early diagnosis and therapy that has become colorectal cancer.
Although increasing disease markers has been found and has been applied to the monitoring of generaI investigation, diagnosis and the curative effect of clinical disease, their clinical application effect also exists obvious deficiency.For example, tumor marker, serum lactic dehydrogenase, carcinomebryonic antigen etc. have been widely used in clinical, but these disease markers also can not satisfy the needs to early diagnosis of cancer far away, its major cause has two aspects: the sensitivity and the specificity of (1) above-mentioned disease markers are relatively low, the index that their detected result can't be made a definite diagnosis as disease; (2) early diagnostic rate of disease should present positive correlation with the effect of treatment, and above-mentioned any disease markers also is difficult to satisfy this requirement of disease early diagnosis.With the cancer is example, tumour differentiation classification specificity is strong excessively, the whole susceptibility of tumour is lower, the censorship sample is difficult to take repeatedly, sample is preserved defectives such as requirement condition height owing to exist, cost an arm and a leg simultaneously, therefore under existence conditions, be difficult to the existing tumor marker of wide popularization and application.And some traditional medicine means detect as histocyte and to exist its inherent defective, and the position of drawing materials is improper, histocyte sample material deficiency or people will cause mistaken diagnosis for lacking experience etc.Though other technology for example iconography has been widely used in the inspection and the diagnosis of disease, it still exists significant limitation on disease degree qualitative.Therefore at present be necessary very much to seek the novel, sensitive of the above-mentioned defective that can remedy existing marker and use disease detection marker easily.
MiRNA, English microRNA by name is the non-coding strand micro ribonucleic acid molecule that a class is about 19 to 23 Nucleotide.They are high conservative on evolving, and with many normal physiological activity of animal, closely related as biont growth, tissue differentiation, natural death of cerebral cells and energy metabolism etc., also exist closely simultaneously and get in touch with the generation of numerous disease and development.The nearest expression level of discovering several miRNAs in lymphocytic leukemia and the Burkitt lymphoma all has downward modulation (Lawrie CH in various degree, Gal S, Dunlop HM et al.Detection of elevated levels of tumor-associated microRNAs in serum of patients with diffuse large B-cell lymphoma.Br J Haematol 2008; 141:672-675); When analyzing the miRNA expression of comparing in people's lung cancer, the breast cancer tissue, discovery has the expression level of some tissue specificity miRNAs with respect to healthy tissues variation (Garofalo M to take place, Quintavalle C, Di Leva G et al.MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer.Oncogene 2008).There are some researches prove that also miRNA has influenced the generation and the development of cardiovascular disordeies such as myocardial hypertrophy, heart failure, atherosclerosis, and close association (Tryndyak VP is arranged with metabolic diseases such as type ii diabetes, Ross SA, Beland FA, Pogribny IP.Down-regulation of the microRNAs miR-34a, miR-127, and miR-200b in rat liver during hepatocarcinogenesis induced by a methyl-deficient diet.Mol Carcinog.2008 Oct 21).Exist positive connection between these experimental result prompting miRNA expression and specific variations and disease generation and the development.
Owing to play vital role beyond imagination in the expression regulation of miRNA after genetic transcription, therefore the cognation below it exists with disease: at first, the variation of miRNA may be the cause of disease, this is because the supressor of disease and the promotion factor all may be the target sites of miRNA, when disorderly expression has taken place earlier miRNA itself, promote the miRNA expression amount of the factor to reduce such as the original disease that suppresses, the miRNA expression amount that perhaps suppresses the disease supressor has raise, its net result all can cause the whole disorderly of downstream series of genes change of Expression and some path, and then the generation that induces an illness; Secondly, the variation of miRNA also may be the result of disease, this is because when disease (as cancer) takes place, can cause the losing of chromosome segment, the sudden change of gene or the violent amplification of chromosome segment, if miRNA just in time is positioned at this varied sections, its expression amount will take place to change extremely significantly so.Therefore, the miRNA molecule can be used as the new disease markers of a class fully in theory, and its specific variations is inevitable to be associated with disease generation development.MiRNA can also by miRNA that suppresses to raise in the lysis or the miRNA of crossing down-regulated expression, might greatly be alleviated the generation and the development of disease as the potential drug target simultaneously.
Domestic existing at present with the correlative study of miRNA as disease markers, as Chinese patent application CN100999765A and CN101298630A, they all choose account for the 4th of malignant tumour sickness rate colorectal carcinoma as research object, find after deliberation, during the colon benign polypus develops into malignant tumour, some miRNA molecules all exist specific variations, and have set up a kind of more responsive, more accurate method of making a definite diagnosis colorectal carcinoma in early days by the specific variations of measuring miRNA in view of the above.Yet because drawing materials of tissue sample is not easy to make the widespread use clinically of this method to be restricted.
Summary of the invention
For overcoming this defective, the applicant will study sight and invest more easily acquisition, even the blood that just can collect in the routine physical examination.Because blood can be circulated to whole body institute in a organized way, and to cell delivery nutrition and remove refuse, so blood can reflect the physiological and pathological situation of whole machine body, and its detected result has directive significance to HUMAN HEALTH.Exist multiple protein in the known blood serum, as total protein, albumin, sphaeroprotein etc., multiple lipid is as HDL cholesterol, triglyceride etc., multiple saccharic, pigment, ionogen and inorganic salt, plurality of enzymes, as amylase, alkaline phosphatase, acid phosphatase, the plain lipase of courage, zymohexase etc., also compiled multiple signaling molecule simultaneously from body tissue's organ, as cytokine, hormone etc.At present, the diagnosis of disease only is confined to above-mentioned biochemical indicator in the blood serum, the still report of serum-free/blood plasma miRNA.Thinking in people's traditional concept does not have ribonucleic acid molecule in the blood serum, though have also can be degraded to small molecule segment very soon by rnase and detect less than.But, because the miRNA molecule is made up of 19 to 23 nucleotide units, having structural singularity and relative stability, they very likely are present in the blood serum.One of the present application people Zhang Chenyu professor's early-stage Study is verified, stably have miRNA in the blood serum, and each disease there is its specific variation collection of illustrative plates (Chen et al:Characterization of microRNAs in serum:a novel class of biomarkers for diagnosis of cancer and other diseases.Cell Res.2008 Oct; 18 (10): 997).
For seeking colorectal cancer certification mark thing and it accurately being detected, the applicant has carried out the research of the following aspects based on available research achievements:
(1) specific variations of blood serum miRNA in the research colorectal cancer pathogenic process;
(2) by being used to detect the biochip of blood serum miRNA and the variation that sequencing technologies is measured colorectal cancer blood serum miRNA;
What (3) will screen expresses the big class blood serum miRNA molecular application of difference degree in blood serum miRNA detection technique under colorectal cancer and normal physiological state, preparation is applied to the biochip and the diagnostic kit in fields such as diagnosis of colorectal carcinoma.
Research by above-mentioned dependency to blood serum miRNA and colorectal cancer, the applicant has proposed specific miRNA with stable existence in the blood serum as colorectal cancer certification mark thing, set up the method for the specific miRNA of stable existence in a kind of vitro detection blood serum, carry out the early diagnosis of colorectal cancer by the specific variations that detects specific miRNA, disease is identified and course of disease monitoring, recurrence and prognosis, the prediction that complication takes place can further be carried out drug effect simultaneously and judge, medicine guide, individualized treatment, the effective components of Chinese medicinal screening, plant researchs such as heap sort.
Purpose of the present invention at first provides a kind of colorectal cancer certification mark thing, described marker comprise following in human serum/blood plasma in the ripe body of stable existence and detectable miRNA (Mature microRNA) any one or more than one (for example 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,4,75,76,77,78,79,80,81,82,83,84,85 or 86 kind), preferred arbitrarily two or more:
Let-7b, let-7c, miR-122, miR-125a-5p, miR-125b, miR-128a, miR-128b, miR-133a, miR-134, miR-139-3p, miR-139-5p, miR-145, miR-146a, miR-150, miR-152, miR-193a-5p, miR-197, miR-199a-3p, miR-199a-5p, miR-199b-3p, miR-22, miR-221, miR-222, miR-223, miR-23a, miR-23b, miR-24, miR-25, miR-27a, miR-27b, miR-28-3p, miR-29a, miR-30d, miR-320, miR-323-3p, miR-330-3p, miR-339-3p, miR-339-5p, miR-342-3p, miR-342-5p, miR-361-5p, miR-382, miR-423-3p, miR-423-5p, miR-361-5p, miR-382, miR-423-3p, miR-423-5p, miR-432, miR-433, miR-486-3p, miR-495, miR-543, miR-574-3p, miR-584, miR-598, miR-744, miR-766, miR-92a, miR-92b, miR-99a, miR-99b, let-7f, let-7g, miR-100, miR-106a, miR-106b, miR-142-3p, miR-144, miR-148a, miR-15a, miR-16, miR-17, miR-182, miR-183, miR-18a, miR-194, miR-19b, miR-20a, miR-20b, miR-29b, miR-340, miR-362-5p, miR-374a, miR-424, miR-451, miR-454, miR-7 and miR-96.
Above-mentioned blood serum can derive from human body live body, tissue, organ and/or corpse.
Another object of the present invention provides the method that detects above-mentioned colorectal cancer marker, can further estimate the state of human body mammary cancer by this method.
Above-mentioned detection method is selected from inverse transcription polymerase chain reaction method (RT-PCR), real time fluorescent quantitative poly chain reaction method (Real-time PCR), Northern blot hybridization method (Northern blotting), rnase protection analysis method (RNase protection assay), Solexa sequencing technologies (Solexa sequencing technology) or biochip method.
Above-mentioned RT-PCR method is a preferred method, may further comprise the steps:
1) extraction experimenter's the total RNA of blood serum (for example extracting by Trizol reagent) obtains the cDNA sample by the RNA reverse transcription reaction; Perhaps collect experimenter's blood serum sample, carry out reverse transcription reaction with blood serum as damping fluid and prepare the cDNA sample;
2) carry out the PCR reaction with miRNA design primer;
3) carry out the agarose gel electrophoresis of PCR product;
4) EB dyeing back observations under ultraviolet lamp;
Above-mentioned Real-time PCR method is another preferred method, may further comprise the steps:
1) extraction experimenter's the total RNA of blood serum (for example extracting by Trizol reagent) obtains the cDNA sample by the RNA reverse transcription reaction; Perhaps carry out reverse transcription reaction as damping fluid and prepare the cDNA sample with experimenter's blood serum;
2) design primer with miRNA;
3) add fluorescent probe and carry out the PCR reaction;
4) detection and comparison blood serum sample are with respect to the variation of the amount of miRNA in normal serum/blood plasma.
Above-mentioned Northern blotting method may further comprise the steps:
1) extraction experimenter's the total RNA of blood serum (for example extracting) by Trizol reagent;
2) carry out sex change PAGE electrophoresis and film shift experiment;
3) preparation isotopic labeling miRNA probe;
4) carry out the film hybridization;
5) isotropic substance signal detection is as phosphorus screen scanning detecting result.
Above-mentioned RNase protection assay method comprises the steps:
1) carries out the synthetic of antisense RNA probes, isotopic labeling and purifying;
2) extraction experimenter's the total RNA of blood serum (for example extracting) by Trizol reagent;
3) RNA after will extracting is dissolved in the hybridization buffer and adds antisense RNA probes and carries out hybridization;
4) adding the RNase Digestive system reacts;
5) carry out electrophoresis and radioautograph;
6) analytical results.
Above-mentioned Solexa sequencing technology method comprises the steps:
1) extraction experimenter's the total RNA of blood serum (for example extracting) by Trizol reagent;
2) carry out the PAGE electrophoresis and reclaim 17-27nt RNA molecule;
34) adaptor prime enzyme being associated in 3 ' and 5 ' of small RNA molecular holds;
4) carry out checking order after the RT-PCR reaction;
5) data analysis and processing.
Above-mentioned biochip method comprises the steps:
1) with the ripe body storehouse dot matrix of whole more than 1,000 kinds of miRNAs in blood of human body/blood plasma and prepare biochip;
2) extraction experimenter's the total RNA of blood serum (for example extracting) by Trizol reagent;
3) separate miRNA by post;
4) utilize T4 RNA ligase enzyme to carry out the miRNA fluorescent mark;
5) carry out hybridization with biochip;
6) Data Detection and analysis.
Employed blood serum derives from experimenter's live body, tissue, organ and/or corpse in the aforesaid method.
The present invention can analyze the variation tendency and the variable quantity of blood serum miRNA in colorectal cancer takes place by aforesaid method, and the dependency of they and colorectal cancer.Therefore, the method of stable existence and detectable 86 kinds of miRNAs can further be estimated the state of human body colorectal cancer in the above human body blood serum, and then can a kind of prediction, diagnosis, discriminating are provided and/or estimate the method for colorectal cancer for people, mainly 86 kinds of specific miRNAs are that so-called colorectal cancer certification mark thing is realized to this method in experimenter's blood serum by detecting.
Another purpose of the present invention provides above-mentioned colorectal cancer certification mark thing in preparation, prediction, diagnosis, discriminating and/or the reagent of evaluation colorectal cancer or the application in the instrument, comprises preparation reagent corresponding box and biochip.
The present invention also provides a kind of miRNA probe combinations that is used to detect colorectal cancer certification mark thing, also i.e. prediction, the miRNA probe combinations of diagnosis and/or evaluation colorectal cancer, described probe combinations comprise in the probe shown in the following nucleotide sequence any one or more than one (for example 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,4,75,76,77,78,79,80,81,82,83,84,85 or 86 kind), preferred arbitrarily two or more:
Let-7b, let-7c, miR-122, miR-125a-5p, miR-125b, miR-128a, miR-128b, miR-133a, miR-134, miR-139-3p, miR-139-5p, miR-145, miR-146a, miR-150, miR-152, miR-193a-5p, miR-197, miR-199a-3p, miR-199a-5p, miR-199b-3p, miR-22, miR-221, miR-222, miR-223, miR-23a, miR-23b, miR-24, miR-25, miR-27a, miR-27b, miR-28-3p, miR-29a, miR-30d, miR-320, miR-323-3p, miR-330-3p, miR-339-3p, miR-339-5p, miR-342-3p, miR-342-5p, miR-361-5p, miR-382, miR-423-3p, miR-423-5p, miR-361-5p, miR-382, miR-423-3p, miR-423-5p, miR-432, miR-433, miR-486-3p, miR-495, miR-543, miR-574-3p, miR-584, miR-598, miR-744, miR-766, miR-92a, miR-92b, miR-99a, miR-99b, let-7f, let-7g, miR-100, miR-106a, miR-106b, miR-142-3p, miR-144, miR-148a, miR-15a, miR-16, miR-17, miR-182, miR-183, miR-18a, miR-194, miR-19b, miR-20a, miR-20b, miR-29b, miR-340, miR-362-5p, miR-374a, miR-424, miR-451, miR-454, miR-7 and miR-96.
| miRNA | Corresponding probe sequence | Sequence numbering |
| let-7b | AACCACACAACCTACTACCTCA | SEQ?ID?NO.1 |
| let-7c | AACCATACAACCTACTACCTCA | SEQ?ID?NO.2 |
| hasmiR-122 | CAAACACCATTGTCACACTCCA | SEQ?ID?NO.3 |
| miR-125a-5p | TCACAGGTTAAAGGGTCTCAGGGA | SEQ?ID?NO.4 |
| miR-125b | TCACAAGTTAGGGTCTCAGGGA | SEQ?ID?NO.5 |
| miR-128a | AAAAGAGACCGGTTCACTGTGA | SEQ?ID?NO.6 |
| miR-128b | GAAAGAGACCGGTTCACTGTGA | SEQ?ID?NO.7 |
| miR-133a | ACAGCTGGTTGAAGGGGACCAA | SEQ?ID?NO.8 |
| miR-134 | CCCTCTGGTCAACCAGTCACA | SEQ?ID?NO.9 |
| miR-139-3p | ACTCCAACAGGGCCGCGTCTCC | SEQ?ID?NO.10 |
| miR-139-5p | CTGGAGACACGTGCACTGTAGA | SEQ?ID?NO.11 |
| miR-145 | AAGGGATTCCTGGGAAAACTGGAC | SEQ?ID?NO.12 |
| miR-146a | AACCCATGGAATTCAGTTCTCA | SEQ?ID?NO.13 |
| miR-150 | CACTGGTACAAGGGTTGGGAGA | SEQ?ID?NO.14 |
| miR-152 | CCCAAGTTCTGTCATGCACTGA | SEQ?ID?NO.15 |
| miR-193a-5p | TCATCTCGCCCGCAAAGACCCA | SEQ?ID?NO.16 |
| miR-197 | GCTGGGTGGAGAAGGTGGTGAA | SEQ?ID?NO.17 |
| miR-199a-3p | TAACCAATGTGCAGACTACTGT | SEQ?ID?NO.18 |
| miR-199a-5p | GAACAGGTAGTCTGAACACTGGG | SEQ?ID?NO.19 |
| miR-199b-3p | TAACCAATGTGCAGACTACTGT | SEQ?ID?NO.20 |
| miR-22 | ACAGTTCTTCAACTGGCAGCTT | SEQ?ID?NO.21 |
| miR-221 | GAAACCCAGCAGACAATGTAGCT | SEQ?ID?NO.22 |
| miR-222 | GAGACCCAGTAGCCAGATGTAGCT | SEQ?ID?NO.23 |
| miR-223 | GGGGTATTTGACAAACTGACA | SEQ?ID?NO.24 |
| miR-23a | GGAAATCCCTGGCAATGTGAT | SEQ?ID?NO.25 |
| miR-23b | GGTAATCCCTGGCAATGTGAT | SEQ?ID?NO.26 |
| miR-24 | CTGTTCCTGCTGAACTGAGCCA | SEQ?ID?NO.27 |
| miR-25 | TCAGACCGAGACAAGTGCAATG | SEQ?ID?NO.28 |
| miR-27a | GCGGAACTTAGCCACTGTGAA | SEQ?ID?NO.29 |
| miR-27b | GCAGAACTTAGCCACTGTGAA | SEQ?ID?NO.30 |
| miR-28-3p | TCCAGGAGCTCACAATCTAGTG | SEQ?ID?NO.31 |
| miR-29a | AACCGATTTCAGATGGTGCTA | SEQ?ID?NO.32 |
| miR-30d | CTTCCAGTCGGGGATGTTTACA | SEQ?ID?NO.33 |
| miR-320 | TTCGCCCTCTCAACCCAGCTTTT | SEQ?ID?NO.34 |
| miR-323-3p | AGAGGTCGACCGTGTAATGTG | SEQ?ID?NO.35 |
| miR-330-3p | TCTCTGCAGGCCGTGTGCTTTGC | SEQ?ID?NO.36 |
| miR-339-3p | CGGCTCTGTCGTCGAGGCGCTCA | SEQ?ID?NO.37 |
| miR-339-5p | CGTGAGCTCCTGGAGGACAGGGA | SEQ?ID?NO.38 |
| miR-342-3p | ACGGGTGCGATTTCTGTGTGAGA | SEQ?ID?NO.39 |
| miR-342-5p | TCAATCACAGATAGCACCCCT | SEQ?ID?NO.40 |
| miR-361-5p | GTACCCCTGGAGATTCTGATAA | SEQ?ID?NO.41 |
| miR-382 | CGAATCCACCACGAACAACTTC | SEQ?ID?NO.42 |
| miR-423-3p | ACTGAGGGGCCTCAGACCGAGCT | SEQ?ID?NO.43 |
| miR-423-5p | AAAGTCTCGCTCTCTGCCCCTCA | SEQ?ID?NO.44 |
| miR-432 | CCACCCAATGACCTACTCCAAGA | SEQ?ID?NO.45 |
| miR-433 | ACACCGAGGAGCCCATCATGAT | SEQ?ID?NO.46 |
| miR-486-3p | ATCCTGTACTGAGCTGCCCCG | SEQ?ID?NO.47 |
| miR-495 | AAAGAAGTGCACCATGTTTGTTT | SEQ?ID?NO.48 |
| miR-543 | AAGAAGTGCACCGCGAATGTTT | SEQ?ID?NO.49 |
| miR-574-3p | TGTGGGTGTGTGCATGAGCGTG | SEQ?ID?NO.50 |
| miR-584 | CTCAGTCCCAGGCAAACCATAA | SEQ?ID?NO.51 |
| miR-598 | TGACGATGACAACGATGACGTA | SEQ?ID?NO.52 |
| miR-744 | TGCTGTTAGCCCTAGCCCCGCA | SEQ?ID?NO.53 |
| miR-766 | GCTGAGGCTGTGGGGCTGGAGT | SEQ?ID?NO.54 |
| miR-92a | ACAGGCCGGGACAAGTGCAATA | SEQ?ID?NO.55 |
| miR-92b | GGAGGCCGGGACGAGTGCAATA | SEQ?ID?NO.56 |
| miR-99a | CACAAGATCGGATCTACGGGTT | SEQ?ID?NO.57 |
| miR-99b | CGCAAGGTCGGTTCTACGGGTG | SEQ?ID?NO.58 |
| let-7f | AACTATACAATCTACTACCTCA | SEQ?ID?NO.59 |
| let-7g | ACTGTACAAACTACTACCTCA | SEQ?ID?NO.60 |
| miR-100 | CACAAGTTCGGATCTACGGGTT | SEQ?ID?NO.61 |
| miR-101 | CTTCAGTTATCACAGTACTGTA | SEQ?ID?NO.62 |
| miR-106a | GCTACCTGCACTGTAAGCACTTTT | SEQ?ID?NO.63 |
| miR-106b | ATCTGCACTGTCAGCACTTTA | SEQ?ID?NO.64 |
| miR-142-3p | TCCATAAAGTAGGAAACACTACA | SEQ?ID?NO.65 |
| miR-144 | CTAGTACATCATCTATACTGTA | SEQ?ID?NO.66 |
| miR-148a | ACAAAGTTCTGTAGTGCACTGA | SEQ?ID?NO.67 |
| miR-15a | CACAAACCATTATGTGCTGCTA | SEQ?ID?NO.68 |
| miR-16 | CGCCAATATTTACGTGCTGCTA | SEQ?ID?NO.69 |
| miR-17 | CTACCTGCACTGTAAGCACTTTG | SEQ?ID?NO.70 |
| miR-182 | TGTGAGTTCTACCATTGCCAAA | SEQ?ID?NO.71 |
| miR-183 | CAGTGAATTCTACCAGTGCCATA | SEQ?ID?NO.72 |
| miR-18a | TATCTGCACTAGATGCACCTTA | SEQ?ID?NO.73 |
| miR-194 | TCCACATGGAGTTGCTGTTACA | SEQ?ID?NO.74 |
| miR-19b | TCAGTTTTGCATGGATTTGCACA | SEQ?ID?NO.75 |
| miR-20a | CTACCTGCACTATAAGCACTTTA | SEQ?ID?NO.76 |
| miR-20b | CTACCTGCACTATGAGCACTTTG | SEQ?ID?NO.77 |
| miR-29b | AACACTGATTTCAAATGGTGCTA | SEQ?ID?NO.78 |
| miR-340 | GGCTATAAAGTAACTGAGACGGA | SEQ?ID?NO.79 |
| miR-362-5p | ACTCACACCTAGGTTCCAAGGATT | SEQ?ID?NO.80 |
| miR-374a | CACTTATCAGGTTGTATTATAA | SEQ?ID?NO.81 |
| miR-424 | TTCAAAACATGAATTGCTGCTG | SEQ?ID?NO.82 |
| miR-451 | AAACTCAGTAATGGTAACGGTTT | SEQ?ID?NO.83 |
| miR-454 | ACCCTATAAGCAATATTGCACTA | SEQ?ID?NO.84 |
| miR-7 | CAACAAAATCACTAGTCTTCCA | SEQ?ID?NO.85 |
| miR-96 | GCAAAAATGTGCTAGTGCCAAA | SEQ?ID?NO.86 |
The present invention also provides a kind of test kit that is used to detect the colorectal cancer marker, also promptly predicts, diagnoses, differentiates and/or estimate the test kit of colorectal cancer, and this test kit comprises the instrument that detects above-mentioned marker.Preferably, wherein said instrument comprises the above-mentioned miRNA probe combinations that is used to detect the colorectal cancer marker; More preferably, described instrument also comprises archaeal dna polymerase (being used for catalytic dna synthetic enzyme in the PCR reaction), deoxyribonucleotide mixture (dNTP mixture).
The miRNA primer of the specific variations relevant with colorectal cancer that screen or its corresponding probe sequence collected in the PCR test kit (RT-PCR or Real-time PCR) can prepare the diagnosis of colorectal carcinoma test kit.
The present invention also provides a kind of biochip that is used to detect the colorectal cancer marker, also promptly predicts, diagnoses, differentiates and/or estimate the biochip of colorectal cancer, and this biochip comprises the element that detects above-mentioned marker.Preferably, wherein said element comprises the above-mentioned combination that is used to detect the miRNA probe any one or more than one of colorectal cancer marker.
With the reverse complementary sequence of the miRNA of the specific variations relevant that screen with colorectal cancer as probe points at chip, just made specially blood serum miRNA detection of biological chip at colorectal cancer.
Particularly, in above-mentioned any containing in above a kind of combination, method, test kit or the biochip to 86 kinds of miRNA markers, described evaluation experimenter's colorectal cancer state is for measuring the colorectal cancer state after the experimenter gives determinand, the activity that prevents and/or treats colorectal cancer that specifically is used to screen determinand (medicine that is used for the treatment of colorectal cancer); Described evaluation experimenter's colorectal cancer state is diagnosis and/or differential diagnosis experimenter's disease; Described evaluation experimenter's colorectal cancer state is for estimating the validity that experimenter's disease is treated; Described evaluation experimenter's colorectal cancer state predicts that for colorectal cancer is taken place the experimenter described generation colorectal cancer is specially the generation of colorectal cancer complication and/or the recurrence of colorectal cancer.
It is also more loaded down with trivial details and coarse at present disease to be carried out the traditional biological chemistry and the Protocols in Molecular Biology of clinical diagnosis.The new technique that might be used for medical diagnosis on disease that development in recent years is got up has gene chip and protein (antibody) chip technology etc.The measured mRNA level of gene chip changes the change that can not reflect real protein level fully.Because proteinic biological activity and post transcriptional modificaiton such as glycosylation, phosphorylation etc. are closely related.And for numerous disease detected, biochip technology can't detect marker molecules in body fluid and the blood.Protein (antibody) chip technology and proteomic techniques also have its limitation.Particularly contain ten hundreds of albumen and polypeptide fragments in the blood serum in the human body, their concentration distribution are wide, clearly Bao Dao albumen seldom, quantification just still less.In the huge protein group of this quantity, look for the protein that close association is arranged with specified disease, and understand its effect in lesion tissue and remain an extremely large order, and lacking perfect antibody resource will be a bottleneck problem of restriction antibody chip technical development.Blood serum miRNA detection technique, biochip and diagnostic kit based on the blood serum miRNA are combined as a whole the peculiar property and the conventional molecular Biological Detection technology of blood serum miRNA dexterously, they analyze the composition of miRNA in the colorectal cancer blood serum in high-throughput ground apace, and clinical applicability is extremely strong.Because the physiological status variation of organ-tissue can cause the change that the blood serum miRNA is formed, so the blood serum miRNA can be used as " disease fingerprint ", the early diagnosis of realization colorectal cancer.
In sum, the present invention has following advantage:
The specific blood serum miRNA that (1) will filter out is as novel colorectal cancer marker, have the pedigree of detecting wide, highly sensitive, detect cost low, draw materials conveniently, sample advantages such as (blood serum-20 ℃ deposit get final product) easy to store, this method can be widely used in related works such as general investigation of desease, becomes the effective means of early diagnosis disease.
(2) the blood serum miRNA with low specificity and the muting sensitivity that the improvement individual difference that single marker was difficult to overcome is brought, significantly improves the early stage diagnosis and treatment of the clinical recall rate and the realization disease of disease as new disease markers.
(3) advantage of blood serum miRNA detection technique is, its detection be a series of disease-related marker, thereby can overcome difference (being age, sex, race, diet and environment etc.) between the individual patient, and this single just disease markers a major obstacle can't going beyond.
In a word, the present invention can further be applied to make a definite diagnosis in early days colorectal cancer, this new blood serum colorectal cancer marker not only provides basic substance for people fully understand the mechanism of colorectal cancer on molecular level, has also quickened clinical disease diagnosis and has learned and therapeutic progress.Superiority based on the blood serum miRNA, believe in the near future, will become the part of routine physical examination to the blood serum miRNA diagnostic techniques of seriously disease such as cancer, and the relevant gene therapy of miRNA also can use widely, conquers these diseases and is no longer a dream.
Description of drawings
Fig. 1 shows the RT-PCR result of direct detected part miRNA in the normal human serum.
Fig. 2 shows and extracts in the normal human serum RNA and detect the wherein RT-PCR result of miRNA.
Fig. 3 shows the miRNA RT-PCR result of direct detected partially stabilized expression in mouse, rat, tire ox, calf and the horse serum respectively.
MiRNA in Fig. 4 A to 4B demonstration diabetes and the osteosarcoma patients serum/blood plasma and normal people's differential expression
Embodiment
Below, describe embodiments of the invention in conjunction with the accompanying drawings in detail.Be understandable that specific implementations described here represents that by way of example it is not as limitation of the present invention.Under the situation that does not deviate from the scope of the invention, principal character of the present invention can be used for various embodiments.One skilled in the art will appreciate that maybe and can confirm that only use normal experiment, many equivalents can both be applied in the particular step described herein.These equivalent places of being considered to and are covered by claim within the scope of the present invention.
The RT-PCR of miRNA experiment in embodiment 1 blood serum
Use the various miRNAs of stable existence in RT-PCR scientific discovery and reference and the animal serum/blood plasma, and its expression amount is quite abundant.Concrete steps are:
(1) collection mouse, rat, normal people and some patient's blood serum;
(2) preparation cDNA sample.This operation has two kinds of schemes, a kind of scheme is for directly to carry out reverse transcription reaction with 10 μ l blood serum, another kind of is to use Trizol reagent (Invitrogen company) to extract the total RNA of blood serum (the 10ml blood serum is the RNA about the about 10 μ g of energy enrichment usually) earlier, obtains cDNA by the RNA reverse transcription reaction then.The reaction system of reverse transcription comprises 4 μ l, 5 * AMV buffer, 2 μ l 10mMeach dNTP mixture (Takara company), 0.5 μ l RNase Inhibitor (Takara company), 2 μ l AMV (Takara company) and 1.5 μ l gene specific reverse primer miscellanys.Reactions steps is 16 ℃ hatched 15 minutes, and 42 ℃ were reacted 1 hour, and hatched 5 minutes for 85 ℃;
(3) PCR and electrophoresis observation.CDNA is diluted by 1/50, get the cDNA after 1 μ l dilutes, add 0.3 μ l Taq enzyme (Takara company), 0.2 μ l 10 μ M forward primers, the general reverse primer of 0.2 μ l, 10 μ M, 1.2 μ l 25mM MgCl2,1.6 μ l 2.5mM each dNTP mixture (Takara company), 2 μ l, 10 * PCR buffer, 13.5 μ lH20,20 μ l systems are carried out PCR.The reaction conditions of PCR is: carried out 1 circulation → 95 ℃, 15 seconds in 95 ℃, 5 minutes, carried out 40 circulations in 60 ℃, 1 minute.The PCR product is got 10 μ l and is carried out 3% agarose gel electrophoresis, and EB dyeing back is observed under ultraviolet lamp.
Concrete experimental result is seen Fig. 1.Fig. 1 is to be research object with the serum of taking from the normal people, serum is directly carried out the experimental result of RT-PCR.Select for use the ripe body of whole more than the 1000 kinds of miRNAs of people to carry out the PCR reaction, Fig. 1 is 12 kinds of miRNAs wherein.They are respectively the specific miRNA miR-181a of hemocyte, miR-181b, miR-223, miR-142-3p, miR-142-5p, miR-150, miRNA miR-1, miR-133a, miR-206 from cardiac muscle and skeletal muscle, from miRNA miR-9, the miR-124a of cerebral tissue, and from the miRNA miR-122a of liver.Above-mentioned as can be seen from the results four kinds of tissue-derived miRNAs can both detect in blood, be not that the ripe body of whole more than 1000 kinds of miRNAs all has high abundance to express in blood serum, some miRNA is very micro-, even can not normally detect.
In order further to verify these miRNAs of stable existence in the blood serum, extract the RNA in the normal human serum earlier, select for use the ripe body of whole more than the 1000 kinds of miRNAs of people to carry out the PCR experiment then, the result is as shown in Figure 2.The result of Fig. 2 and the result of Fig. 1 are very identical, and the PCR product is single, show that these two kinds of experimental techniques can both detect the expression and the abundance of human serum miRNA, prove stably to have multiple tissue-derived miRNA in human serum.
In Fig. 1 and Fig. 2, U6 is that molecular weight is the snRNA of 100bp, internal reference molecule as the miRNA experiment, the specific miRNA miR-181a of hemocyte (181a) represented respectively in remaining 12 code name, miR-181b (181b), miR-223 (223), miR-142-3p (142-3p), miR-142-5p (142-5p), miR-150 (150), miRNA miR-1 (1) from cardiac muscle and skeletal muscle, miR-133a (133a), miR-206 (206), miRNA miR-9 (9) from cerebral tissue, miR-124a (124a), and from the miRNA miR-122a (122a) of liver.
In addition, use the same method and detected the expression and the abundance of more than 1000 kind of miRNA in mouse, rat, tire ox, calf and the horse serum, the same miRNA of different tissue sources of finding has stably express in mouse, rat, tire ox, calf and horse serum, the result as shown in Figure 3.
The real-time PCR of miRNA experiment in embodiment 2 blood serum
In order to study the special variation of blood serum miRNA in the colorectal cancer lysis, carried out the quantitative PCR experiment of blood serum miRNA.Quantitative PCR experiment principle and experimental procedure are the same with RT-PCR, and unique not being both added fluorescence dye EVA GREEN in PCR.What instrument used is ABI Prism 7300 quantitative real time PCR Instruments, and reaction conditions is to carry out 1 circulation → 95 ℃, 15 seconds in 95 ℃, 5 minutes, carries out 40 circulations in 60 ℃, 1 minute.Data processing method is a Δ Δ CT method, and CT is made as the cycle number of reacting when reaching thresholding, and then each miRNA can be represented with equation 2-Δ CT with respect to the expression amount of standard confidential reference items, wherein Δ CT=CT sample-CT confidential reference items.Patients serum/plasma sample and normal human serum/plasma sample are directly carried out reverse transcription reaction, react the wherein amount of contained miRNA by quantitative PCR.
Choose osteosarcoma and diabetic serum sample, the ripe body of whole more than 1000 kinds of miRNAs of choosing simultaneously carries out the PCR experiment.The result is shown in Fig. 4 A and Fig. 4 B.The amount of miRNA has the mediation of going up downward modulation respectively with respect to the ratio of normal people's amount in osteosarcoma and the diabetic serum, and same tissue-derived miRNA intensity of variation difference in various disease, show that the blood serum miRNA has specific variations in various disease, they can be used as the marker of the new medical diagnosis on disease of a class.
Embodiment 3 is used to diagnose the blood serum miRNA chip of colorectal cancer
The chip operation flow process is:
(1) extract total RNA in the blood serum, the denaturing formaldehyde gel electrophoresis detects the quality of total RNA;
(2) separation of miRNA: get 50-100 μ g total RNA Ambion ' s miRNA Isolation Kit (Cat#.1560) and separate miRNA;
(3) fluorescent mark of miRNA sample: utilize T4 RNA ligase enzyme marking method to carry out fluorescent mark, and then, be used for chip hybridization after drying up with the dehydrated alcohol precipitation;
(4) hybridization and cleaning: RNA is dissolved in (15% methane amide in the 16 μ L hybridization solutions; 0.2%SDS; 3 * SSC; 50 * Denhardt ' s solution), spend the night in 42 ℃ of hybridization.After hybridization finishes, contain 0.2%SDS earlier about 42 ℃, washed in the liquid of 2 * SSC 4 minutes, then room temperature was washed 4 minutes in 0.2 * SSC liquid, promptly can be used for scanning after slide dries;
(5) chip scanning: chip scans with LuxScan 10K/A two channels laser scanner;
(6) data extract and analysis: adopt the LuxScan3.0 image analysis software that chip image is analyzed, picture signal is converted into numerary signal, analyze with SAM at last and select difference expression gene.
The class blood serum miRNA probe that the differential expression degree under colorectal cancer and normal physiological state of quantitative PCR technique and biochip technology double verification is big is used to prepare biochip, and method is the same.This chip is compared with traditional die, and manufacture craft and operating process do not have significant improvement, but this chip has been simplified probe library, will significantly reduce the cost of manufacture and the production time of chip thus, is easy to preparation.The specific aim and the practicality of chip have also been increased simultaneously.With the practice of this chip input, only need patient's blood serum and just can find disease in early days without any need for other tissue, help to instruct and diagnose and treat.
Embodiment 4 is used for the minuteness ribonucleic acid reagent kit of diagnosis of colorectal carcinoma and prediction
Be used for the diagnosis of colorectal cancer, the generation of disease complication and the prediction of recurrence, therapeutic evaluation, and the manufacture craft and the operating process of the minuteness ribonucleic acid reagent kit of the screening of active constituents of medicine, evaluating drug effect are based on solexa sequencing technologies and biochip technology.
All detect the comfortable hospital of sample standard deviation and are diagnosed as colorectal cancer patients and equity age and other normal people of homogeny (contrast) in the present embodiment.Compare the microRNA that expresses rising in the colorectal cancer patients serum with normal human serum as shown in table 1.Compare the microRNA that expresses decline in the colorectal cancer patients serum with normal human serum as shown in table 2.
Table 1 is compared with normal human serum and express the microRNA that raises in the colorectal cancer patients serum
| Sequence number | Title | Copy number in the normal serum | Copy number in the |
| 1 | has-let-7b | 731.28 | 6269.66 |
| 2 | has-let-7c | 13.16 | 80.64 |
| 3 | has-miR-122 | 0.00 | 3298.12 |
| 4 | has-miR-125a-5p | 0.00 | 52.42 |
| 5 | has-miR-125b | 0.00 | 28.22 |
| 6 | has-miR-128a | 0.00 | 245.95 |
| 7 | has-miR-128b | 0.00 | 185.47 |
| 8 | has-miR-133a | 0.00 | 36.29 |
| 9 | has-miR-134 | 0.00 | 213.69 |
| 10 | has-miR-139-3p | 0.00 | 80.64 |
| 11 | has-miR-139-5p | 0.00 | 48.38 |
| 12 | has-miR-145 | 0.00 | 44.35 |
| 13 | has-miR-146a | 108.80 | 2132.89 |
| 14 | has-miR-150 | 0.00 | 270.14 |
| 15 | has-miR-152 | 0.00 | 40.32 |
| 16 | has-miR-193a-5p | 0.00 | 104.83 |
| 17 | has-miR-197 | 0.00 | 60.48 |
| 18 | has-miR-199a-3p | 10.59 | 1149.10 |
| 19 | has-miR-199a-5p | 0.00 | 52.42 |
| 20 | has-miR-199b-3p | 10.59 | 1149.10 |
| 21 | has-miR-22 | 167.99 | 1209.58 |
| 22 | has-miR-221 | 0.00 | 6422.87 |
| 23 | has-miR-222 | 14.30 | 1673.25 |
| 24 | has-miR-223 | 41.02 | 2919.12 |
| 25 | has-miR-23a | 12.95 | 2322.39 |
| 26 | has-miR-23b | 0.00 | 149.18 |
| 27 | has-miR-24 | 31.22 | 1693.41 |
| 28 | has-miR-25 | 738.64 | 6447.06 |
| 29 | has-miR-27a | 0.00 | 149.18 |
| 30 | has-miR-27b | 0.00 | 189.50 |
| 31 | has-miR-28-3p | 0.00 | 28.22 |
| 32 | has-miR-29a | 36.80 | 306.43 |
| 33 | has-miR-30d | 200.97 | 1657.12 |
| 34 | has-miR-320 | 526.39 | 17692.12 |
| 35 | has-miR-323-3p | 0.00 | 20.16 |
| 36 | has-miR-330-3p | 0.00 | 96.77 |
| 37 | has-miR-339-3p | 0.00 | 290.30 |
| 38 | has-miR-339-5p | 11.08 | 298.36 |
| 39 | has-miR-342-3p | 0.00 | 161.28 |
| 40 | has-miR-342-5p | 0.00 | 24.19 |
| 41 | has-miR-361-5p | 0.00 | 32.26 |
| 42 | has-miR-382 | 0.00 | 157.25 |
| 43 | has-miR-423-3p | 15.89 | 1245.87 |
| 44 | has-miR-423-5p | 198.01 | 13978.71 |
| 45 | has-miR-432 | 0.00 | 157.25 |
| 46 | has-miR-433 | 0.00 | 100.80 |
| 47 | has-miR-486-3p | 0.00 | 92.73 |
| 48 | has-miR-495 | 0.00 | 56.45 |
| 49 | has-mi?R-543 | 0.00 | 48.38 |
| 50 | has-miR-574-3p | 0.00 | 72.57 |
| 51 | has-miR-584 | 0.00 | 282.24 |
| 52 | has-miR-598 | 0.00 | 116.93 |
| 53 | has-miR-744 | 0.00 | 395.13 |
| 54 | has-miR-766 | 0.00 | 52.42 |
| 55 | has-miR-92a | 339.47 | 4128.70 |
| 56 | has-miR-92b | 0.00 | 60.48 |
| 57 | has-miR-99a | 0.00 | 32.26 |
| 58 | has-miR-99b | 0.00 | 133.05 |
Table 2 is compared with normal human serum and express the microRNA that raises in the colorectal cancer patients serum
| Sequence number | Title | Copy number in the normal serum | Copy number in the |
| 1 | has-let-7f | 2009.11 | 56.45 |
| 2 | has-let-7g | 2058.34 | 294.33 |
| 3 | has-miR-100 | 25.75 | 0.00 |
| 4 | has-miR-101 | 2510.38 | 0.00 |
| 5 | has-miR-106a | 157.57 | 24.19 |
| 6 | has-miR-106b | 1400.94 | 16.13 |
| 7 | has-miR-142-3p | 326.82 | 0.00 |
| 8 | has-miR-144 | 317.75 | 16.13 |
| 9 | has-miR-148a | 83.80 | 0.00 |
| 10 | has-miR-15a | 465.23 | 48.38 |
| 11 | has-miR-16 | 6805.84 | 649.14 |
| 12 | has-miR-17 | 556.71 | 72.57 |
| 13 | has-miR-182 | 77.77 | 0.00 |
| 14 | has-miR-183 | 36.90 | 0.00 |
| 15 | has-miR-18a | 119.69 | 0.00 |
| 16 | has-miR-194 | 79.39 | 0.00 |
| 17 | has-miR-19b | 483.56 | 16.13 |
| 18 | has-miR-20a | 1484.05 | 24.19 |
| 19 | has-miR-20b | 98.67 | 0.00 |
| 20 | has-miR-29b | 24.57 | 0.00 |
| 21 | has-miR-340 | 108.95 | 0.00 |
| 22 | has-miR-362-5p | 26.31 | 0.00 |
| 23 | has-miR-374a | 39.62 | 0.00 |
| 24 | has-miR-424 | 22.88 | 0.00 |
| 25 | has-miR-451 | 58299.32 | 2112.73 |
| 26 | has-miR-454 | 22.03 | 0.00 |
| 27 | has-miR-7 | 476.64 | 0.00 |
| 28 | has-miR-96 | 24.10 | 0.00 |
In sum, we have filtered out 86 kinds of blood serum miRNAs that can carry out the diagnosis of colorectal carcinoma assessment.These blood serum miRNAs comprise that 58 kinds of blood serum miRNAs that raise and 28 kinds descend in the colorectal cancer patient in the colorectal cancer patient the blood serum miRNA.
The described blood serum miRNA that can be used for diagnosis of colorectal carcinoma and assessment is prepared into chip, simultaneously, also can adopts the fluorescence real-time quantitative PCR method, detect the above blood serum minuteness ribonucleic acid,, be used for the diagnosis of colorectal cancer as test kit.Test kit comprises reagent such as a collection of blood serum miRNA primer, Taq enzyme, dNTP.
Above chip and test kit can be used to diagnose and/or differentiate the curative effect of colorectal cancer and assessment colorectal cancer medicine, the activity that can be used for screening the colorectal cancer medicine simultaneously; Also can carry out the prediction of colorectal cancer complication and colorectal cancer recurrence.
Claims (14)
1. colorectal cancer certification mark thing, it is characterized in that described marker comprise following in human serum/blood plasma in stable existence and the ripe body of detectable miRNA any one or more than one:
Let-7b, let-7c, miR-122, miR-125a-5p, miR-125b, miR-128a, miR-128b, miR-133a, miR-134, miR-139-3p, miR-139-5p, miR-145, miR-146a, miR-150, miR-152, miR-193a-5p, miR-197, miR-199a-3p, miR-199a-5p, miR-199b-3p, miR-22, miR-221, miR-222, miR-223, miR-23a, miR-23b, miR-24, miR-25, miR-27a, miR-27b, miR-28-3p, miR-29a, miR-30d, miR-320, miR-323-3p, miR-330-3p, miR-339-3p, miR-339-5p, miR-342-3p, miR-342-5p, miR-361-5p, miR-382, miR-423-3p, miR-423-5p, miR-361-5p, miR-382, miR-423-3p, miR-423-5p, miR-432, miR-433, miR-486-3p, miR-495, miR-543, miR-574-3p, miR-584, miR-598, miR-744, miR-766, miR-92a, miR-92b, miR-99a, miR-99b, let-7f, let-7g, miR-100, miR-106a, miR-106b, miR-142-3p, miR-144, miR-148a, miR-15a, miR-16, miR-17, miR-182, miR-183, miR-18a, miR-194, miR-19b, miR-20a, miR-20b, miR-29b, miR-340, miR-362-5p, miR-374a, miR-424, miR-451, miR-454, miR-7 and miR-96.
2. colorectal cancer certification mark thing according to claim 1, it is characterized in that described marker comprise following in human serum/blood plasma in the ripe body of stable existence and detectable miRNA any two or more:
Let-7b, let-7c, miR-122, miR-125a-5p, miR-125b, miR-128a, miR-128b, miR-133a, miR-134, miR-139-3p, miR-139-5p, miR-145, miR-146a, miR-150, miR-152, miR-193a-5p, miR-197, miR-199a-3p, miR-199a-5p, miR-199b-3p, miR-22, miR-221, miR-222, miR-223, miR-23a, miR-23b, miR-24, miR-25, miR-27a, miR-27b, miR-28-3p, miR-29a, miR-30d, miR-320, miR-323-3p, miR-330-3p, miR-339-3p, miR-339-5p, miR-342-3p, miR-342-5p, miR-361-5p, miR-382, miR-423-3p, miR-423-5p, miR-361-5p, miR-382, miR-423-3p, miR-423-5p, miR-432, miR-433, miR-486-3p, miR-495, miR-543, miR-574-3p, miR-584, miR-598, miR-744, miR-766, miR-92a, miR-92b, miR-99a, miR-99b, let-7f, let-7g, miR-100, miR-106a, miR-106b, miR-142-3p, miR-144, miR-148a, miR-15a, miR-16, miR-17, miR-182, miR-183, miR-18a, miR-194, miR-19b, miR-20a, miR-20b, miR-29b, miR-340, miR-362-5p, miR-374a, miR-424, miR-451, miR-454, miR-7 and miR-96.
3. according to the colorectal cancer certification mark thing described in the claim 1 to 2, it is characterized in that described blood serum derives from human body live body, tissue, organ and/or corpse.
4. the detection method of any described colorectal cancer certification mark thing of claim 1 to 3 is characterized in that being selected from inverse transcription polymerase chain reaction method, real time fluorescent quantitative poly chain reaction method, Northern blot hybridization method, rnase protection analysis method, Solexa sequencing technologies or biochip method.
5. detection method according to claim 4 is characterized in that described inverse transcription polymerase chain reaction method may further comprise the steps:
1) extraction experimenter's the total RNA of blood serum obtains the cDNA sample by the RNA reverse transcription reaction; Perhaps carry out reverse transcription reaction as damping fluid and prepare the cDNA sample with experimenter's blood serum;
2) carry out the PCR reaction with miRNA design primer;
3) carry out the agarose gel electrophoresis of PCR product;
4) EB dyeing back observations under ultraviolet lamp.
6. detection method according to claim 4 is characterized in that described real time fluorescent quantitative poly chain reaction method may further comprise the steps:
1) extraction experimenter's the total RNA of blood serum obtains the cDNA sample by the RNA reverse transcription reaction; Perhaps carry out reverse transcription reaction as damping fluid and prepare the cDNA sample with experimenter's blood serum sample;
2) design primer with miRNA;
3) add fluorescent probe and carry out the PCR reaction;
4) detection and comparison blood serum sample are with respect to the variation of the amount of miRNA in normal serum/blood plasma.
7. a prediction, diagnosis and/or estimate the method for colorectal cancer is characterized in that, described method comprise detect in stable existence in following human serum/blood plasma and the detectable miRNA maturation body any one or more than one:
Let-7b, let-7c, miR-122, miR-125a-5p, miR-125b, miR-128a, miR-128b, miR-133a, miR-134, miR-139-3p, miR-139-5p, miR-145, miR-146a, miR-150, miR-152, miR-193a-5p, miR-197, miR-199a-3p, miR-199a-5p, miR-199b-3p, miR-22, miR-221, miR-222, miR-223, miR-23a, miR-23b, miR-24, miR-25, miR-27a, miR-27b, miR-28-3p, miR-29a, miR-30d, miR-320, miR-323-3p, miR-330-3p, miR-339-3p, miR-339-5p, miR-342-3p, miR-342-5p, miR-361-5p, miR-382, miR-423-3p, miR-423-5p, miR-361-5p, miR-382, miR-423-3p, miR-423-5p, miR-432, miR-433, miR-486-3p, miR-495, miR-543, miR-574-3p, miR-584, miR-598, miR-744, miR-766, miR-92a, miR-92b, miR-99a, miR-99b, let-7f, let-7g, miR-100, miR-106a, miR-106b, miR-142-3p, miR-144, miR-148a, miR-15a, miR-16, miR-17, miR-182, miR-183, miR-18a, miR-194, miR-19b, miR-20a, miR-20b, miR-29b, miR-340, miR-362-5p, miR-374a, miR-424, miR-451, miR-454, miR-7 and miR-96.
8. claim 1 or 2 described colorectal cancer certification mark things are in preparation prediction, diagnosis, discriminating and/or the reagent of evaluation colorectal cancer or the purposes in the instrument.
9. miRNA probe combinations that is used to detect colorectal cancer certification mark thing, it is characterized in that described combination comprise in the following probe sequence any one or more than one:
10. a test kit that is used to detect the colorectal cancer marker is characterized in that described test kit comprises the instrument that test right requires 1 or 2 described certification mark things.
11. test kit according to claim 10 is characterized in that described instrument comprises the described probe combinations of claim 9.
12. test kit according to claim 10 is characterized in that described instrument also comprises archaeal dna polymerase and/or deoxyribonucleotide mixture.
13. a biochip that is used to detect colorectal cancer certification mark thing is characterized in that described biochip comprises the element that test right requires 1 or 2 described certification mark things.
14. biochip according to claim 13 is characterized in that the element of described biochip comprises the described probe combinations of claim 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102384489A CN101988060A (en) | 2009-07-30 | 2010-07-28 | Marker for detecting colon and rectum cancer as well as detection method, kit and biological chip thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910305027.0 | 2009-07-30 | ||
| CN200910305027 | 2009-07-30 | ||
| CN2010102384489A CN101988060A (en) | 2009-07-30 | 2010-07-28 | Marker for detecting colon and rectum cancer as well as detection method, kit and biological chip thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101988060A true CN101988060A (en) | 2011-03-23 |
Family
ID=43744854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102384489A Pending CN101988060A (en) | 2009-07-30 | 2010-07-28 | Marker for detecting colon and rectum cancer as well as detection method, kit and biological chip thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101988060A (en) |
Cited By (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102191327A (en) * | 2011-04-18 | 2011-09-21 | 中国人民解放军总医院 | Kit for forecasting death rate of patients with sepsis and application thereof |
| CN102443648A (en) * | 2011-12-20 | 2012-05-09 | 苏州福英基因科技有限公司 | In-situ hybridization detection kit for microRNA-182 level in early stage of pathological evolution of various cancers, and detection method and application thereof |
| CN102533984A (en) * | 2011-12-19 | 2012-07-04 | 苏州福英基因科技有限公司 | Horizontal in-situ hybridization detection kit and detection method as well as application for MICRORNA17-3P in earlier stage of cancer pathologic evolution |
| CN102676523A (en) * | 2012-05-16 | 2012-09-19 | 北京旷博生物技术有限公司 | Breast cancer molecular marker miR-139-5p |
| CN103074431A (en) * | 2013-01-14 | 2013-05-01 | 山东大学齐鲁医院 | Special primer, kit and method for testing minRNA-128 in colorectal cancer serum |
| CN103173448A (en) * | 2013-02-07 | 2013-06-26 | 上海市胸科医院 | Early-stage lung adenocarcinoma miRNA (micro ribonucleic acid) specific expression profile and reverse transcription primer and application thereof |
| CN103205495A (en) * | 2013-04-03 | 2013-07-17 | 复旦大学附属肿瘤医院 | Gene for colorectal cancer prognosis and application thereof |
| CN103361437A (en) * | 2013-07-29 | 2013-10-23 | 中国人民解放军第二军医大学 | Application of miR-15a as molecular marker for clinical screening of aortic dissection and kit of miR-15a |
| CN103614468A (en) * | 2013-11-18 | 2014-03-05 | 常州市第一人民医院 | Kit for judging therapeutic effect of late gastric cancer, and application method thereof |
| CN103966327A (en) * | 2014-05-07 | 2014-08-06 | 新乡医学院 | Application of miR-27a and diagnostic kit thereof |
| CN104195238A (en) * | 2014-08-15 | 2014-12-10 | 深圳市晋百慧生物有限公司 | Marker for detecting intestinal cancer and application of marker |
| WO2015018308A1 (en) * | 2013-08-06 | 2015-02-12 | BGI Shenzhen Co.,Limited | Biomarkers for colorectal cancer |
| WO2015054220A1 (en) * | 2013-10-07 | 2015-04-16 | Georgetown University | Compositions and methods for identification of relapse risk and treatment in patients with colorectal cancer |
| CN104651521A (en) * | 2011-10-21 | 2015-05-27 | 巴塞罗那临床医院 | Plasma microRNA for the detection of early colorectal cancer |
| CN105985953A (en) * | 2015-01-27 | 2016-10-05 | 中国医学科学院肿瘤医院 | Application of micro RNA 100 |
| CN107326092A (en) * | 2017-08-25 | 2017-11-07 | 深圳市恩普电子技术有限公司 | Applications and colorectal cancer detection kit of the related miRNA of colorectal cancer as biomarker |
| CN107881239A (en) * | 2017-12-27 | 2018-04-06 | 广西壮族自治区肿瘤防治研究所 | The miRNA marker related to colorectal cancer transfer and its application in blood plasma |
| CN107881238A (en) * | 2017-12-27 | 2018-04-06 | 广西壮族自治区肿瘤防治研究所 | The miRNA marker related to colorectal cancer prognosis and its application |
| CN108004323A (en) * | 2017-12-27 | 2018-05-08 | 广西壮族自治区肿瘤防治研究所 | In tissue relevant miRNA marker and its application are shifted with colorectal cancer |
| CN108048551A (en) * | 2017-12-20 | 2018-05-18 | 中国人民解放军第四军医大学 | The application of miR-139-3p and its antagonist in diagnose and treat disease of skeletal system |
| WO2018170619A1 (en) * | 2017-03-18 | 2018-09-27 | 深圳市博奥康生物科技有限公司 | Dual-mirna inhibition expression vector and application thereof |
| CN109929914A (en) * | 2017-12-15 | 2019-06-25 | 安徽普元生物科技股份有限公司 | MicroRNA 744 (MIR744) nucleic acid quantitative determination reagent kit (PCR- fluorescence probe method) |
| CN110261495A (en) * | 2018-11-01 | 2019-09-20 | 青岛大学附属医院 | A kind of method and its detection kit for identifying colorectal cancer biomarker |
| CN111455052A (en) * | 2020-04-21 | 2020-07-28 | 首都医科大学附属北京友谊医院 | Exosome RNA molecular marker combination for early diagnosis of colorectal cancer and application thereof |
| CN111996255A (en) * | 2020-08-24 | 2020-11-27 | 复旦大学附属中山医院 | Diagnostic marker for colorectal malignant polyps and use thereof |
| CN113981096A (en) * | 2021-11-30 | 2022-01-28 | 无锡市疾病预防控制中心 | Plasma miRNA marker for diagnosing colorectal cancer and application thereof |
| CN114150050A (en) * | 2014-04-10 | 2022-03-08 | 中国人民解放军总医院 | System, method and establishment of method for IgA nephropathy detection |
| CN115998879A (en) * | 2023-01-09 | 2023-04-25 | 广东医科大学附属医院 | Application of miR-92b-3p inhibitor in preparation of epilepsy treatment drugs |
| WO2023115601A1 (en) * | 2021-12-23 | 2023-06-29 | 广西百谷生物科技有限公司 | Mirna detection kit for prognosis of colorectal cancer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101296702A (en) * | 2005-09-12 | 2008-10-29 | 俄亥俄州立大学研究基金会 | Compositions and methods for the diagnosis and therapy of BCL2-associated cancers |
-
2010
- 2010-07-28 CN CN2010102384489A patent/CN101988060A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101296702A (en) * | 2005-09-12 | 2008-10-29 | 俄亥俄州立大学研究基金会 | Compositions and methods for the diagnosis and therapy of BCL2-associated cancers |
Non-Patent Citations (2)
| Title |
|---|
| BRACONI AND PATEL: "MicroRNA Expression Profiling: A Molecular Tool for Defining the Phenotype of Hepatocellular Tumors", 《HEPATOLOGY》 * |
| 刘宝瑞, 谢 丽: "miRNA:新一代肿瘤生物标志", 《临床肿瘤学杂志》 * |
Cited By (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102191327A (en) * | 2011-04-18 | 2011-09-21 | 中国人民解放军总医院 | Kit for forecasting death rate of patients with sepsis and application thereof |
| CN104651521A (en) * | 2011-10-21 | 2015-05-27 | 巴塞罗那临床医院 | Plasma microRNA for the detection of early colorectal cancer |
| CN102533984A (en) * | 2011-12-19 | 2012-07-04 | 苏州福英基因科技有限公司 | Horizontal in-situ hybridization detection kit and detection method as well as application for MICRORNA17-3P in earlier stage of cancer pathologic evolution |
| CN102443648A (en) * | 2011-12-20 | 2012-05-09 | 苏州福英基因科技有限公司 | In-situ hybridization detection kit for microRNA-182 level in early stage of pathological evolution of various cancers, and detection method and application thereof |
| CN102676523A (en) * | 2012-05-16 | 2012-09-19 | 北京旷博生物技术有限公司 | Breast cancer molecular marker miR-139-5p |
| CN102676523B (en) * | 2012-05-16 | 2013-05-29 | 北京旷博生物技术有限公司 | Breast cancer molecular marker miR-139-5p |
| CN103074431A (en) * | 2013-01-14 | 2013-05-01 | 山东大学齐鲁医院 | Special primer, kit and method for testing minRNA-128 in colorectal cancer serum |
| CN103074431B (en) * | 2013-01-14 | 2013-12-11 | 山东大学齐鲁医院 | Special primer, kit and method for testing minRNA-128 in colorectal cancer serum |
| CN103173448A (en) * | 2013-02-07 | 2013-06-26 | 上海市胸科医院 | Early-stage lung adenocarcinoma miRNA (micro ribonucleic acid) specific expression profile and reverse transcription primer and application thereof |
| CN103205495B (en) * | 2013-04-03 | 2014-11-19 | 复旦大学附属肿瘤医院 | Gene for colorectal cancer prognosis and application thereof |
| CN103205495A (en) * | 2013-04-03 | 2013-07-17 | 复旦大学附属肿瘤医院 | Gene for colorectal cancer prognosis and application thereof |
| CN103361437A (en) * | 2013-07-29 | 2013-10-23 | 中国人民解放军第二军医大学 | Application of miR-15a as molecular marker for clinical screening of aortic dissection and kit of miR-15a |
| WO2015018308A1 (en) * | 2013-08-06 | 2015-02-12 | BGI Shenzhen Co.,Limited | Biomarkers for colorectal cancer |
| US10526659B2 (en) | 2013-08-06 | 2020-01-07 | Bgi Shenzhen Co., Limited | Biomarkers for colorectal cancer |
| US10351913B2 (en) * | 2013-10-07 | 2019-07-16 | Georgetown University | Compositions and methods for identification of relapse risk and treatment in patients with colorectal cancer |
| WO2015054220A1 (en) * | 2013-10-07 | 2015-04-16 | Georgetown University | Compositions and methods for identification of relapse risk and treatment in patients with colorectal cancer |
| US20160258024A1 (en) * | 2013-10-07 | 2016-09-08 | Georgetown University | Compositions and methods for identification of relapse risk and treatment in patients with colorectal cancer |
| CN103614468A (en) * | 2013-11-18 | 2014-03-05 | 常州市第一人民医院 | Kit for judging therapeutic effect of late gastric cancer, and application method thereof |
| CN103614468B (en) * | 2013-11-18 | 2015-09-16 | 常州市第一人民医院 | A kind of test kit and using method thereof judging late gastric cancer treatment curative effect |
| CN114150050A (en) * | 2014-04-10 | 2022-03-08 | 中国人民解放军总医院 | System, method and establishment of method for IgA nephropathy detection |
| CN103966327A (en) * | 2014-05-07 | 2014-08-06 | 新乡医学院 | Application of miR-27a and diagnostic kit thereof |
| CN103966327B (en) * | 2014-05-07 | 2016-02-03 | 济宁医学院 | The application of a kind of miR-27a and diagnostic kit thereof |
| CN104928360B (en) * | 2014-08-15 | 2018-04-24 | 深圳市晋百慧生物有限公司 | For detecting label and its application of intestinal cancer |
| CN104928360A (en) * | 2014-08-15 | 2015-09-23 | 深圳市晋百慧生物有限公司 | Marker for detecting intestinal cancer and application thereof |
| CN104195238A (en) * | 2014-08-15 | 2014-12-10 | 深圳市晋百慧生物有限公司 | Marker for detecting intestinal cancer and application of marker |
| US10131956B2 (en) | 2014-08-15 | 2018-11-20 | Shenzhen Genebiohealth Co. Ltd. | Marker used for detection of colon cancer, and application thereof |
| CN105985953A (en) * | 2015-01-27 | 2016-10-05 | 中国医学科学院肿瘤医院 | Application of micro RNA 100 |
| CN105985953B (en) * | 2015-01-27 | 2018-12-21 | 中国医学科学院肿瘤医院 | The application of microRNA 100 |
| WO2018170619A1 (en) * | 2017-03-18 | 2018-09-27 | 深圳市博奥康生物科技有限公司 | Dual-mirna inhibition expression vector and application thereof |
| CN107326092A (en) * | 2017-08-25 | 2017-11-07 | 深圳市恩普电子技术有限公司 | Applications and colorectal cancer detection kit of the related miRNA of colorectal cancer as biomarker |
| CN107326092B (en) * | 2017-08-25 | 2021-07-20 | 深圳市恩普电子技术有限公司 | Application of colorectal cancer-related miRNA as biomarker and colorectal cancer detection kit |
| CN109929914A (en) * | 2017-12-15 | 2019-06-25 | 安徽普元生物科技股份有限公司 | MicroRNA 744 (MIR744) nucleic acid quantitative determination reagent kit (PCR- fluorescence probe method) |
| CN108048551A (en) * | 2017-12-20 | 2018-05-18 | 中国人民解放军第四军医大学 | The application of miR-139-3p and its antagonist in diagnose and treat disease of skeletal system |
| CN107881239B (en) * | 2017-12-27 | 2021-04-13 | 广西壮族自治区肿瘤防治研究所 | miRNA marker related to colorectal cancer metastasis in plasma and application thereof |
| CN107881238A (en) * | 2017-12-27 | 2018-04-06 | 广西壮族自治区肿瘤防治研究所 | The miRNA marker related to colorectal cancer prognosis and its application |
| CN108004323B (en) * | 2017-12-27 | 2021-03-30 | 广西壮族自治区肿瘤防治研究所 | miRNA marker related to colorectal cancer metastasis in tissue and application thereof |
| CN108004323A (en) * | 2017-12-27 | 2018-05-08 | 广西壮族自治区肿瘤防治研究所 | In tissue relevant miRNA marker and its application are shifted with colorectal cancer |
| CN107881239A (en) * | 2017-12-27 | 2018-04-06 | 广西壮族自治区肿瘤防治研究所 | The miRNA marker related to colorectal cancer transfer and its application in blood plasma |
| CN110261495A (en) * | 2018-11-01 | 2019-09-20 | 青岛大学附属医院 | A kind of method and its detection kit for identifying colorectal cancer biomarker |
| CN111455052A (en) * | 2020-04-21 | 2020-07-28 | 首都医科大学附属北京友谊医院 | Exosome RNA molecular marker combination for early diagnosis of colorectal cancer and application thereof |
| CN111996255A (en) * | 2020-08-24 | 2020-11-27 | 复旦大学附属中山医院 | Diagnostic marker for colorectal malignant polyps and use thereof |
| CN111996255B (en) * | 2020-08-24 | 2023-03-14 | 复旦大学附属中山医院 | Diagnostic marker for colorectal malignant polyps and use thereof |
| CN113981096A (en) * | 2021-11-30 | 2022-01-28 | 无锡市疾病预防控制中心 | Plasma miRNA marker for diagnosing colorectal cancer and application thereof |
| WO2023115601A1 (en) * | 2021-12-23 | 2023-06-29 | 广西百谷生物科技有限公司 | Mirna detection kit for prognosis of colorectal cancer |
| CN115998879A (en) * | 2023-01-09 | 2023-04-25 | 广东医科大学附属医院 | Application of miR-92b-3p inhibitor in preparation of epilepsy treatment drugs |
| CN115998879B (en) * | 2023-01-09 | 2024-03-15 | 广东医科大学附属医院 | Application of miR-92b-3p inhibitor in preparation of epilepsy treatment drugs |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10774386B2 (en) | Serum or plasma microRNA as biomarkers for non-small cell lung cancer | |
| CN101988060A (en) | Marker for detecting colon and rectum cancer as well as detection method, kit and biological chip thereof | |
| CN101942502B (en) | Pancreatic cancer marker, and detection method, kit and biochip thereof | |
| US9637793B2 (en) | Pancreatic cancer markers, and detecting methods, kits, biochips thereof | |
| US10011880B2 (en) | Serum/plasma MicroRNAs and uses thereof | |
| AU2012245580B2 (en) | miRNA-based universal screening test (UST) | |
| Kashyap et al. | Cell-free miRNAs as non-invasive biomarkers in breast cancer: Significance in early diagnosis and metastasis prediction | |
| CN103937876B (en) | For diagnosing and treat the method and composition of adenocarcinoma of esophagus | |
| CN101988059B (en) | Gastric cancer detection marker and detecting method thereof, kit and biochip | |
| CN101988061A (en) | Breast cancer detecting marker as well as detecting method, kit and biological chip thereof | |
| AU2017213457B2 (en) | Micro-RNA biomarkers and methods of using same | |
| US20080076674A1 (en) | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer | |
| WO2011012074A1 (en) | Detection markers of liver cancer and detection methods, kits and biochips thereof | |
| CN101921759A (en) | Serum/plasma miRNA serum marker related to cervical carcinoma and precancerous lesions thereof and application thereof | |
| GB2535914A (en) | Biomarkers useful for detection of types, grades and stages of human breast cancer | |
| CN100999765A (en) | Biological chip of identifying colon canceration degree using microchanging of RNA | |
| CN101988062A (en) | cervical cancer detection markers and detection method, kit and biochip thereof | |
| US20210079478A1 (en) | Method for assisting in detection of breast cancer | |
| CN107299129B (en) | Application of circulating nucleic acid as breast cancer biomarker | |
| CN104694534B (en) | Non-small cell lung cancer marker, detection method and application thereof | |
| EP2942399A1 (en) | Method for the diagnosis of breast cancer | |
| CN116790760A (en) | Colon cancer specific annular RNA marker, detection primer and application thereof | |
| CN102605094B (en) | Kit for detecting micro ribonucleic acid in blood serum and preparation method thereof | |
| US20230160010A1 (en) | Method for aiding detection of alzheimer' s disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110323 |